36 results about "Kidney Toxicity" patented technology

The invention discloses a macrophage-polymer lipid nanoparticle composite drug delivery system, a preparation method thereof and application of the macrophage-polymer lipid nanoparticle composite drug delivery system in cryptococcus infection resistance. According to the drug delivery system, alpha-linolenic acid (ALA), high molecular weight chitosan oligosaccharide (HCOS) and amphotericin B (AmB) are used as raw materials to construct nanoparticles AmB-PLHNs, the nanoparticles are loaded in macrophages through the phagocytosis of the macrophages, and the AmB-PLHNs (at) M1 is constructed. AmB is a common medicine for clinically treating Cn infection, but has the problems of toxic and side effects on kidney and incapability of being transferred into the center. The AmB-PLHNs (at) M1 carries AmB-PLHNs to be transferred into the brain according to the blood-brain barrier penetrating characteristic of M1 type macrophages, and the brain entering efficiency of the medicine is improved. By combining the phagocytosis of macrophages on cryptococcus, the inflammation immune regulation function of the macrophages and the bacteriostatic action of the drug-loaded nanoparticles, the drug-loaded nano-particles are used for treating Cn central infection, and the toxic and side effects of AmB are reduced.

The invention discloses a bacteriophage lyase and application thereof, and particularly relates to a bacteriophage lyase with an amino acid sequence as shown in SEQ INNO.2. The bacteriophage lyase can inhibit the growth of escherichia coli, staphylococcus and salmonella, can be used as an antibacterial substance in splitting gram-negative bacteria and can be used for preparing drugs for resisting gram-negative bacteria. The lyase can be used independently or compounded with other substances, the use concentration of antibiotics can be reduced by combining the lyase with the antibiotics, toxic and side effects (such as renal toxicity of polymyxin) of drugs are reduced, and meanwhile, generation of bacterial drug resistance is delayed. After the lyase and the chitosan are combined for use, remarkable antibacterial activity is generated, the antibacterial effect can be achieved without pre-treatment on bacteria, and the practicability is improved.

The invention relates to the technical field of preparation of organoids, and discloses a method for regulating and controlling human induced pluripotent stem cells to differentiate into kidney organoids, which comprises the following steps: resuspending a cell cluster formed by human induced pluripotent stem cells by using a basic differentiation culture solution containing a GSK-3beta inhibitor, inoculating the cell cluster into an ultralow adsorption cell culture plate, and starting to culture, marking the time as the 0th hour of differentiation; and after culturing for 70-76 hours, replacing the basic differentiation culture solution containing the GSK-3beta inhibitor with a basic differentiation culture solution containing a Knockout TM serum substitute (KSR), and continuing to carry out differentiation culture. By adopting the method disclosed by the invention, the human induced pluripotent stem cells can be efficiently, quickly, simply, conveniently and stably subjected to directional induced differentiation into kidney organs containing podocytes, renal tubules and other structures, and the time for constructing a kidney in-vitro model can be shortened, so that the research on kidney diseases, kidney development and the like can be greatly assisted; and a powerful platform is provided for kidney toxicity assessment.

This invention discloses an antimicrobial peptide PA targeting multidrug-resistant Gram-negative bacteria and its application. The amino acid sequence of the antimicrobial peptide PA is shown in SEQ ID NO.1. The antimicrobial peptide PA provided by this invention has a significant antibacterial effect against multidrug-resistant Gram-negative bacteria, and has a rapid bactericidal onset, no hemolysis or cytotoxicity, does not cause nephrotoxicity after treatment, and has good biosafety. It can be used for the treatment of bacterial infections and can also be applied to other scenarios that require bactericidal or antibacterial growth inhibition.

The invention discloses an acute kidney injury nuclear magnetic resonance detection contrast agent as well as a preparation method and application thereof. The lipidosome comprises a first lipid component and a second lipid component, the first lipid component is any one of 1, 2-dipalmitoyl-sn-glycerol-3-phosphorylcholine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine and distearoyl phosphatidylcholine, and the second lipid component is a sterol derivative, and the first lipid component is any one of 1, 2-dipalmitoyl-sn-glycerol-3-phosphorylcholine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine and distearoyl phosphatidylcholine. The molar ratio of the first lipid component to the second lipid component is (1-3): 1. According to the invention, all organic free radicals are used for replacing gadolinium ions, so that renal toxicity and systemic fibrosis risks caused by metal accumulation are eliminated, and the method is especially suitable for imaging of patients with renal insufficiency. The material synthesis process is simple, and the cost is controllable. In addition, the system is seamlessly compatible with clinical 3.0 T MRI equipment, additional hardware transformation is not needed, and popularization and application of AKI bedside rapid imaging diagnosis can be directly promoted.

The invention provides a pharmaceutical composition for treating non-small cell lung cancer and a use method, and belongs to the technical field of tumor immunotherapy. The invention formulates a non-small cell lung cancer weak chemotherapy and anti-vascular immunity triple treatment scheme based on the combination of a low-dose chemotherapy drug pemetrexed, an immune checkpoint inhibitor and an anti-angiogenesis drug. According to the scheme, low-dose pemetrexed is combined with the anti-angiogenesis medicine and the immune checkpoint inhibitor for use, the optimal synergistic effect can be achieved, meanwhile, the renal toxicity and the myelosuppression risk are remarkably reduced, and the pemetrexed medicine composition is expected to become one of the optimal choices for driving gene negative and PD-L1 positive expression non-squamous NSCLC patients, and has a wide application prospect. The device is suitable for old people or patients with poor physical states; especially for patients with negative driver genes and positive PD-L1 expression, the traditional treatment blank is filled, and clinical data shows that survival benefits are remarkable.

The invention discloses application of an aromatic hydrocarbon receptor stimulant in preparation of a medicine for treating diarrhea of weaned piglets and / or inhibiting inflammation, and belongs to the field of biological medicine. According to the present invention, with the PAS-B structural domain of the AHR as the target, the virtual screening technology, the target verification test and the weaned piglet diarrhea pharmacodynamic evaluation test are performed to determine the arctigenin as the AHR strong agonist and the anti-inflammatory drug, and the arctigenin has the good treatment effect on the weaned piglet diarrhea. Experimental results show that 10 mg / kg of arctigenin can significantly relieve diarrhea and hemafecia symptoms of weaned piglets, reduce the content of inflammatory factors in serum and intestinal tissues and improve the intestinal structure of weaned piglets, has no significant cytotoxicity, hepatorenal toxicity and intestinal epithelial cell growth inhibition effect, and can be used for preparing a feed additive for weaned piglets. The compound can be used for preparing medicines for treating diarrhea of weaned piglets. The invention provides a new raw material medicine for treating diarrhea of weaned piglets, and has great economic value and wide application prospect.

The invention discloses a brain-targeted nasal-spray amphotericin B phospholipid complex and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations, the brain-targeted nasal-spray amphotericin B phospholipid complex is prepared by adopting a film dispersion method, and the preparation method comprises the following steps: dissolving 15-hydroxystearic acid polyethylene glycol ester, phospholipid, cholesterol, amphotericin B and optional other auxiliary components in a solvent, removing the solvent until a film is formed, and drying to obtain the brain-targeted nasal-spray amphotericin B phospholipid complex. And carrying out hydration dispersion to obtain the amphotericin B-loaded phospholipid complex. According to the amphotericin B sodium deoxycholate injection, the problems that the traditional amphotericin B sodium deoxycholate injection is high in renal toxicity, the intrathecal injection is poor in solubility, and low in bioavailability and patient compliance, large in side effect and the like due to the fact that the traditional amphotericin B sodium deoxycholate injection is difficult to penetrate through a blood brain After nasal administration, the drug is quickly delivered into the brain, so that the slow release of the drug is realized, the intracerebral bioavailability of the drug is improved, high brain targeting and low systemic toxic and side effects are realized, and good clinical application value and market prospect are achieved.

The invention relates to the technical field of radiopharmaceuticals, and discloses a targeted reversible covalent ligand which comprises a targeted pharmacodynamic group (P), a reversible covalent connection bullet (RCL) and a combined radionuclide group (C), and the targeted reversible covalent ligand has a structural general formula: C-RCL-P, the reversible covalent linked bullet (RCL) is a thiol group-containing similar group linked bullet which can be reversibly combined with a disulfide bond in a target protein, and preferably comprises one of GSH, Lys-Cys, Cys, SeC, GCys and GSECys linkers. The target reversible covalent radiopharmaceutical has the following technical effects that the target reversible covalent radiopharmaceutical constructed by adopting the target reversible covalent ligand containing the RCL has excellent in-vivo pharmacokinetic characteristics, and can increase lesion uptake, lesion radioactivity residence time and imaging contrast, reduce liver and kidney uptake and reduce liver and kidney toxicity. The invention also discloses a targeted reversible covalent radiopharmaceutical as well as a preparation method and application thereof.

The invention relates to the technical field of biological medicine, and discloses an activated cis-platinum reversible coordination complex, coordination nano-micelles thereof and application of the activated cis-platinum reversible coordination complex and the coordination nano-micelles. The activated cis-platinum reversible coordination complex is a complex formed by a coordination material and a metal platinum drug or an activated molecule thereof or a derivative thereof, and the coordination ratio of a coordination group in the coordination material to the metal platinum drug or the activated molecule thereof or the derivative thereof is less than or equal to 2: 1; the coordination material is a coordination phospholipid-like material or a coordination polymer material; the metal platinum medicine or the activated molecule or the derivative thereof is cis-platinum, carboplatin, lobaplatin, epithiaplatin, nedaplatin, oxaliplatin or the activated molecule or the derivative thereof. According to the activated cisplatin reversible coordination complex and the coordination nano-micelle and application thereof, the coordination nano-micelle not only can realize cisplatin controlled release regulated by iron ions, but also can reduce ferroptosis of renal tubular cells and related renal cells by chelating the iron ions, so that the renal toxicity of the cisplatin is efficiently inhibited, and the application value is wide.

The invention provides a bifunctional fusion protein radionuclide marker with a brand new structure model, which has higher labeling rate and radiochemical purity, keeps higher affinity and functional activity, and has proper molecular weight, strong tissue penetrability, good imaging effect, proper cycle half-life period and strong molecular stability. After a target carrier is radiolabeled, the target carrier still shows good affinity and is not affected, has good biological metabolic activity and clearance rate, has the effects of reducing radiation toxicity, kidney toxicity, blood toxicity and non-target organ toxicity, is well enriched in tumor cells, is beneficial to realizing diagnosis and accurate staging of tumor focuses, and can be used as a target carrier to improve the clinical application prospect. Precise radiotherapy of primary focuses and metastatic focuses is achieved, good safety and effectiveness potential are achieved, and good application prospects are achieved in the field of solid tumor treatment.

The invention relates to the field of liposome manufacturing, and discloses an amphotericin B liposome and a preparation method thereof, and the amphotericin B liposome comprises the following components in parts by mass: 1 part of amphotericin B, 5-10 parts of hydrogenated soybean phospholipid (HSPC), 2-4 parts of cholesterol, 1-3 parts of mPEG2000-DSPE, 0.5-1.5 parts of ceramide, 0.3-0.8 part of glycyrrhetinic acid, 0.2-0.5 part of hydroxyapatite nanoparticles (nHAP) and 8-15 parts of a freeze-drying protective agent. The glycyrrhetinic acid is added, and the specific targeting effect of the glycyrrhetinic acid is utilized, so that the in-vitro binding rate of fungal cells of the lipidosome is improved, the enrichment rate of the medicine at an infected part is further improved, and the core problem of renal toxicity caused by non-targeting distribution of a traditional preparation is effectively solved; the hydroxyapatite nanoparticles adsorb medicine molecules to form a medicine-nHAP compound, and the medicine crystallization rate is greatly reduced by combining the synergistic anti-crystallization effect of the freeze-drying protective agent.

The invention relates to the technical field of biology, in particular to a renal tubule 3D printing chip with peripheral capillary vessels and application. The invention provides a renal tubule chip for constructing a renal tubule model with peripheral capillary vessels. The invention also discloses a method for constructing a renal tubule model with peripheral capillary vessels by using the renal tubule chip. The renal tubule model with the peripheral capillary vessels constructed by the method has a renal tubule structure and the peripheral capillary vessel network of the renal tubule, the peripheral capillary vessel network of the renal tubule can be highly simulated from two aspects of an anatomical structure and a physiological process, and a more bionic renal tubule chip model is provided; an animal model and a traditional two-dimensional culture mode can be replaced, and a more accurate platform is provided for in-vitro simulated drug kidney toxicity evaluation, renal function mechanism research, kidney disease engineering modeling and kidney disease treatment drug effectiveness test.

The invention discloses a polymyxin B therapeutic drug monitoring method and application thereof, which can be used for monitoring PB renal toxicity, and has the advantages of high sensitivity, rapidness, convenience and accurate and reliable result. The method comprises the following steps: (1) acquiring the concentrations of the following components of polymyxin B in a biological sample: polymyxin B1, polymyxin B2, polymyxin B3 and isoleucine-polymyxin B1; (2) taking one or more of the following concentration ratios as monitoring data: (polymyxin B + polymyxin B3) / polymyxin B, (polymyxin B1 + isoleucine-polymyxin B1) / (polymyxin B + polymyxin B3), isoleucine-polymyxin B1 / (polymyxin B + polymyxin B3), polymyxin B1 / (polymyxin B + polymyxin B3), polymyxin B1 / (polymyxin B + polymyxin B3), polymyxin B1 / (polymyxin B + polymyxin B3), and polymyxin B1 / polymyxin B; and the isoleucine-polymyxin B1 / polymyxin B, and comparing the monitoring data with a cutoff value (Cuff).

The present disclosure provides a method for evaluating the renal toxicity of a test substance as an improved in vitro evaluation system for evaluating the renal toxicity of a substance, such as a compound, the method comprising the step of contacting the test substance with a renal organoid, higher cytotoxicity of the test substance indicates that the test substance may have renal toxicity.

The invention relates to the technical field of medicaments, and discloses a medicament and a method for relieving inflammatory response of chronic nephropathy by a composition for regulating intestinal flora, the medicament takes'probiotics, prebiotics and postbiotics' as a core, the probiotics contain bifidobacterium lactis and Akk bacteria, the prebiotics are fructo-oligosaccharide-inulin mixture, the postbiotics are butyrin, and the prebiotics and the postbiotics are mixed uniformly. Astragalus polysaccharide / lycium barbarum polysaccharide can be added for synergistic interaction; dosage forms of the enteric capsule, the powder and the oral suspension are divided into enteric capsules, powder and oral suspension, the enteric capsule is suitable for different people groups, inflammation is relieved by repairing intestinal barriers, inhibiting NF-kB channels and optimizing flora, after 12-24 weeks of administration, serum IL-6, TNF-alpha and hs-CRP are reduced by 15%-55%, renal functions and cardiovascular complications are synchronously improved, the enteric capsule is free of kidney toxicity, the adverse reaction rate is smaller than or equal to 5%, and the enteric capsule is suitable for long-term intervention of CKD inflammation.

The application discloses a nucleoside compound with a novel structure, a salt of the nucleoside compound and a preparation method of the nucleoside compound. The nucleoside compound and the salt thereof exhibit a strong inhibitory effect on tumor proliferation in vivo, and do not exhibit obvious side effects. Meanwhile, the compound of the application does not have obvious stomach irritation and kidney toxicity, and shows a good medical application prospect in the treatment of cancer.

The invention relates to the field of cell therapy, in particular to application of NK cells in preparation of drugs for treating fibrosis diseases. The invention discloses application of NK (natural killer) cells in preparation of medicines for treating fibrosis diseases, and compared with nintedanib or pirfenidone, the NK cells have equivalent or even better effects in treatment of pulmonary fibrosis diseases, are higher in safety and do not cause side effects such as hepatotoxicity or renal toxicity. Also disclosed is a method of treating a subject suffering from a fibrotic disease by administering one or more NK cells to the subject.

The application discloses a method for quantitatively analyzing 21 arginine synthesis metabolites in mouse liver, kidney and serum based on liquid chromatography-mass spectrometry technology and application of the method in cantharidin hepatorenal toxicity research. The method comprises the following steps: preparing 21 metabolites and two internal standard solutions; optimizing mass spectrometry multiple reaction monitoring parameters; performing sample analysis after protein precipitation by acetonitrile, nitrogen blowing dry and 50% methanol water reconstitution; and establishing eight concentration level standard curves and adopting a weighted least square method to fit a linear equation. Methodology verification shows that the linear relationship of each metabolite is good (r 2 >0.99), and the precision, accuracy, matrix effect, recovery rate and stability all meet the requirements of biological sample analysis. The method has simple sample pretreatment, high sensitivity and strong specificity, is successfully applied to determination of the content of 21 arginine metabolites in a mouse hepatorenal toxicity model caused by cantharidin, and provides a reliable analysis tool for arginine metabolism research and cantharidin toxicity mechanism exploration.

The invention discloses a purine-like nucleoside phosphamide ester ZL-492 and an application of the purine-like nucleoside phosphamide ester ZL-492 in an antiviral drug. The purine-like nucleoside phosphamide ester ZL-492 is obtained by taking a compound 1 and a compound 2 as raw materials and reacting in an organic solvent in the presence of a magnesium catalyst, and the chemical structural formula of the purine-like nucleoside phosphamide ester ZL-492 is shown in the specification. Researches show that the purine-like nucleoside phosphamide ester ZL-492 has a good application prospect in the aspect of resisting HIV-1 virus infection, especially HIV-lucc / HBX2 and HIV-lucc / JRFL viruses, and the application range of the purine-like nucleoside phosphamide ester ZL-492 in the aspect of resisting HIV-lucc / HBX2 and HIV-lucc / JRFL viruses is widened. The compound has the advantages of remarkably improving the activity of nucleoside drugs, improving the oral absorption efficiency, reducing the administration dosage and frequency, reducing the blood toxicity and kidney toxicity and the like.

The invention relates to an amino ferrocene modified black phosphorus compound containing stable free radicals and a preparation method and application thereof.The amino ferrocene modified black phosphorus compound containing the stable free radicals is obtained by covalently modifying the surface of black phosphorus with amino ferrocene, and the amino ferrocene and the black phosphorus are combined through a P-C-N bond; the compound contains stable free radicals and has room-temperature ferromagnetism. The amino ferrocene modified black phosphorus compound containing the stable free radicals contains the stable free radicals, has room-temperature ferromagnetism, low toxicity and high biological safety, has no renal toxicity and brain deposition risk compared with a traditional gadolinium-based contrast agent, has saturation magnetization (Ms) three times of that of SPIONs under the condition of the same mass Fe content, and has a good application prospect. When in use, the required iron concentration is extremely low, so that cell injury and organ failure can be avoided to a great extent, and the compound can be used for an MRI contrast agent.

The invention discloses a preparation method of a kidney-like organ with an increased in-vitro proximal tubule proportion, and belongs to the field of cytology. The method comprises the following steps: inducing kidney organs by using human embryonic stem cells WIBR3, culturing the WIBR3 cells until the WIBR3 cells can be passaged, and digesting the WIBR3 cells by using Accutase digestive juice; after the digestion is completed, stopping the digestion by using a DMEM-F12 culture medium, collecting a cell suspension, centrifuging, discarding supernate, collecting cell precipitates, and counting; resuspending the collected cell precipitate by using a stem cell culture medium, paving the cell precipitate in a pore plate, adding an apoptosis inhibitor, and uniformly mixing; and carrying out suspension culture on the obtained system by using a kidney organ culture medium for promoting the differentiation of the proximal tubules to obtain the kidney organs with the proportion of the proximal tubules increased. The preparation method is simple, the culture efficiency is high, and the prepared kidney organ with the increased proximal tubule proportion can effectively simulate the kidney organ with the increased proximal tubule proportion in vivo and can also be used for chemical substance kidney toxicity detection.

The present invention relates to an antimicrobial adjuvant containing a biphenyl derivative compound as an active ingredient, and a technology of various uses thereof. The compound of the present invention reduces the dosage of polymyxin antibiotics, which are administered to inhibit the proliferation of gram-negative bacteria, by enhancing the sensitivity of the gram-negative bacteria with respect to the polymyxin antibiotics, is concomitantly administered with the polymyxin antibiotics to show gram-negative bacteria growth inhibitory and killing effects, may notably reduce side effects such as nephrotoxicity, and may prevent or treat sepsis and septic shock due to antibiotic overuse.

The invention discloses an edible polypeptide preparation with diuretic and anti-inflammatory functions as well as a preparation method and application thereof, and the preparation method comprises the following steps: (1) taking fresh pleurotus eryngii, carrying out wet grinding and ball material separation to obtain a pleurotus eryngii aqueous solution, and preparing a primary wet material; (2) performing ultrahigh pressure treatment and centrifugal separation on the first-stage wet material to obtain a pleurotus eryngii extract, and preparing a second-stage wet material; and (3) fully mixing the secondary wet material with water according to a mass ratio of 1: 3-1: 30, adding a compound enzyme preparation, putting the mixture into a radio frequency electromagnetic field for treatment, and purifying and drying after treatment to obtain the polypeptide powder preparation. The polypeptide preparation has no electrolyte disorder / liver and kidney toxicity, has dual effects of diuresis and inflammation diminishing, solves the problems of single effect and poor safety of the existing medicine and complex process of the traditional functional food, provides a safe, efficient and sustainable solution for sub-health and chronic disease patients, and has wide application prospects. And the pharmaceutical composition has remarkable market competitiveness and clinical transformation value.

The application belongs to the field of medicine, and specifically discloses a benzopyran COX-2 inhibitor and application thereof. The benzopyran COX-2 inhibitor is a compound shown in formula (I) or a pharmaceutically acceptable salt, ester, solvate, stereoisomer, prodrug or isotopic variant thereof. The compound shown in formula (I) has good COX-2 selective inhibitory activity, and an optimal compound has an IC 50 as low as 28 nmol / L, can reduce gastrointestinal side effects and renal toxicity, has excellent inhibitory effect on PGE2, has almost no inhibitory effect on hERG channel current, has low cardiotoxicity, has high stability in human and rat liver microsomes, has a long half-life and a fast peak time when administered orally or by injection, and can be used for the treatment of anti-inflammatory analgesic diseases and tumor-related diseases through injection and oral absorption administration.

The application discloses a new use of sildenafil and its salts in combination with ibuprofen. Through pharmacodynamics and toxicology experiments, the application first proposes and verifies that the combination of sildenafil and its salts (sildenafil citrate) and ibuprofen has a significant synergistic effect in treating inflammatory pain, and can effectively reduce the renal toxicity induced by long-term administration of ibuprofen. The application solves the problem that long-term or large-dose use of ibuprofen can induce significant renal toxicity, which seriously limits the long-term, standard and sufficient clinical application of ibuprofen. The composition provided by the application can enhance the analgesic effect of ibuprofen and reduce the renal toxicity of ibuprofen, and has important clinical conversion value and practical application prospect.

The present invention discloses a preparation method of a cisplatin chloride modified blood purification filter membrane and a corresponding purification membrane, which belongs to the field of medical technology. The inventors of the present application have found a blood purification membrane that can provide a blood purification effect and can also achieve the anti-cancer effect by administering anti-cancer drugs through a large number of experiments. The present invention provides a method for effectively combining cisplatin with a blood purification membrane, and allowing cisplatin to be released from the blood purification filter membrane after contact with blood. Cisplatin reaches cancer cells with the blood, thereby playing an anti-cancer role. At the same time, the blood purification membrane can also remove metabolites produced in the anti-cancer process, thereby avoiding the nephrotoxicity caused by cisplatin. The method of the present invention can also increase the binding rate of cisplatin and polyethersulfone, thereby increasing the preparation yield. The cisplatin chloride modified blood purification membrane prepared by the chemical grafting method of the present invention has the effect of slowly releasing cisplatin, and is particularly suitable for blood purification treatment of tumor patients.

The invention relates to the field of biological medicine, in particular to application of atorvastatin in preparation of medicine for preventing and treating renal toxicity caused by vancomycin. The protection effect of atorvastatin on the kidney injury caused by vancomycin is provided for the first time, a kidney injury model is established through vancomycin induction, and it is proved through in-vivo and in-vitro experiments that atorvastatin plays the kidney protection effect through anti-inflammation, anti-oxidation, anti-apoptosis and kidney transporter expression regulation; the kidney toxicity induced by vancomycin is effectively improved. The invention provides a basis for using atorvastatin as a novel medicine for treating kidney injury caused by vancomycin.

The present invention provides a new use of cycloeugenol. The cycloeugenol has a significant ability to eliminate senescent cells in a bleomycin-induced cell senescence model, an etoposide-induced cell senescence model, and a replicative cell senescence model; can significantly inhibit the activity of the anti-apoptotic protein Bcl-2; cycloeugenol selectively eliminates senescent cells while having no obvious liver or kidney toxicity; cycloeugenol can significantly reduce the expression levels of aging biomarkers such as P16 and P21 in naturally aged mice, improve the antioxidant capacity of naturally aged mice, restore the abnormal number of immune cells caused by natural aging, and significantly reduce skin wrinkles in naturally aged mice. The cycloeugenol has a clear anti-aging effect and has broad application prospects in the preparation of anti-aging products.

The invention discloses a dual-modular targeted delivery system and application of the dual-modular targeted delivery system in targeted anti-inflammatory drugs. The dual-modular targeted delivery system comprises an intravenous injection module and a respiratory tract inhalation module, the intravenous injection module is mesenchymal stem cells a-MSCs functionally modified by a first click chemical reaction group, and the respiratory tract inhalation module is drug-loaded nanoparticles b-NPs functionally modified by a second click chemical reaction group; according to the dual-modular targeted delivery system, the drug removal barrier is broken through through conjugate immune camouflage, the alveolar residence time of nanoparticles is prolonged, the drug concentration of a pneumonia focus area is increased, and the treatment effective rate is increased; due to the modular design, the whole-body exposure of NPs is reduced, and the liver and kidney toxicity is reduced; the single-time inhalation dosage is reduced, the patient compliance is improved, and the application prospect is great.